Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-178.00K | -178.00K | -161.00K | -151.00K | -230.00K | EBIT |
-15.84M | -13.90M | -10.44M | -10.91M | -8.69M | EBITDA |
-15.76M | -13.69M | -10.28M | -10.73M | -8.37M | Net Income Common Stockholders |
-16.08M | -13.84M | -10.44M | -10.86M | -8.51M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.05M | 10.38M | 23.77M | 13.76M | 20.43M | Total Assets |
3.22M | 15.97M | 26.57M | 16.48M | 22.66M | Total Debt |
113.00K | 221.00K | 235.00K | 330.00K | 415.00K | Net Debt |
-939.00K | -10.16M | -23.54M | -13.43M | -20.01M | Total Liabilities |
2.78M | 1.80M | 1.11M | 1.41M | 1.57M | Stockholders Equity |
441.00K | 14.17M | 25.46M | 15.07M | 21.09M |
Cash Flow | Free Cash Flow | |||
-11.54M | -15.12M | -9.99M | -10.96M | -8.36M | Operating Cash Flow |
-11.54M | -15.10M | -9.92M | -10.96M | -8.36M | Investing Cash Flow |
0.00 | -21.00K | -70.00K | 0.00 | 0.00 | Financing Cash Flow |
2.20M | 1.73M | 20.01M | 4.29M | 27.78M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.39 | -40.42% | 2.90% | 18.11% | 2.25% | |
39 Underperform | $3.12M | ― | -191.51% | ― | -6.42% | 24.85% | |
37 Underperform | $1.20M | ― | -3325.71% | ― | ― | 79.79% | |
37 Underperform | $4.12M | ― | -222.46% | ― | -7.74% | 93.25% | |
33 Underperform | $1.02M | ― | -233.77% | ― | ― | -97.16% | |
18 Underperform | $931.00K | ― | -21.57% | ― | ― | 97.84% |
On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.